---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-149597"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:49:54.836209+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# enGene Holdings changes name to enGene Therapeutics Inc., signals commercial readiness for detalimogene

## Summary
- Name change to enGene Therapeutics Inc. effective April 8, 2026; tickers ENGN/ENGNW unchanged.
- BLA submission for detalimogene planned for 2H 2026 in BCG-unresponsive NMIBC with CIS.
- Potential approval and commercial launch targeted for 2027.
- New CUSIP numbers: common shares 29286X101, warrants 29286X119.

## SEC filing metadata
- accession: 0001193125-26-149597
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/0001193125-26-149597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/engn-20260407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-149597
- JSON: https://secwatch.observer/filing/0001193125-26-149597.json
- Plain text: https://secwatch.observer/filing/0001193125-26-149597.txt

## Key facts
- Governance Changes
  enGene Therapeutics Inc.: Amended Articles to change corporate name from enGene Holdings Inc. to enGene Therapeutics Inc (effective 2026-04-08).
  - Change: charter amendment
  - Effective: 2026-04-08
  source text: On April 6, 2026, enGene Therapeutics Inc., formerly known as enGene Holdings Inc. (the “Company”), filed a notice of alteration (the “Notice of Alteration”) with the Province of British Columbia Registrar of Companies to change the Company’s corporate name to enGene Therapeutics Inc., effective as of April 8, 2026 (the “Name Change”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/0001193125-26-149597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.